Serum lipids in primary sclerosing cholangitis

BackgroundLimited data are available regarding the serum lipids in primary sclerosing cholangitis.AimsTo determine the lipid levels in patients with primary sclerosing cholangitis.MethodsWe monitored the serum lipid levels annually for up to 6 years in 157 patients included in three previous trials of ursodeoxycholic acid.ResultsThe baseline lipid values were: total cholesterol = 207 mg/dL (127–433); high-density lipoprotein = 56 mg/dL (26–132); low-density lipoprotein = 129 mg/dL (48–334); triglycerides = 102 mg/dL (41–698). Cirrhotic stage was associated with lower levels of total cholesterol (186 mg/dL vs. 217 mg/dL, p = .02). A significant correlation between the liver biochemistries and total and low-density lipoprotein cholesterol levels was observed. Ursodeoxycholic acid, as compared to placebo, significantly decreased total (−27 mg/dL vs. 22 mg/dL, p = .0004) and low-density lipoprotein cholesterol (−24 mg/dL vs. 17 mg/dL, p = .0001). After extended follow-up, small changes in the lipid levels were noticed. The incidence of coronary artery disease was 4%.ConclusionsOur findings suggest that the lipid levels in primary sclerosing cholangitis are often above levels where treatment with lipid-lowering agents is recommended. However, primary sclerosing cholangitis patients seem to have no elevated risk for cardiovascular events. The correlation of total and low-density lipoprotein cholesterol with liver biochemistries implies that mechanisms linked to cholestasis may regulate cholesterol metabolism.